STOCK TITAN

Kodiak Sciences to Present at 2025 Jefferies Global Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Kodiak Sciences (NASDAQ: KOD), a biopharmaceutical company focused on developing treatments for retinal diseases, announced that CEO Victor Perlroth will present at the 2025 Jefferies Global Healthcare Conference. The presentation is scheduled for June 5, 2025, at 9:20am ET in New York City. Investors can access a live webcast of the presentation through Kodiak's investor relations website at ir.kodiak.com, where it will remain available for replay for a limited time after the event.
Kodiak Sciences (NASDAQ: KOD), un'azienda biofarmaceutica specializzata nello sviluppo di trattamenti per le malattie retiniche, ha annunciato che il CEO Victor Perlroth presenterà alla Jefferies Global Healthcare Conference del 2025. La presentazione è prevista per il 5 giugno 2025 alle 9:20 ET a New York City. Gli investitori potranno seguire la diretta streaming della presentazione tramite il sito web delle relazioni con gli investitori di Kodiak all'indirizzo ir.kodiak.com, dove sarà disponibile anche una registrazione per la visione on demand per un periodo limitato dopo l'evento.
Kodiak Sciences (NASDAQ: KOD), una empresa biofarmacéutica enfocada en el desarrollo de tratamientos para enfermedades de la retina, anunció que su CEO, Victor Perlroth, presentará en la Conferencia Global de Salud Jefferies 2025. La presentación está programada para el 5 de junio de 2025 a las 9:20 a.m. ET en la ciudad de Nueva York. Los inversores podrán acceder a una transmisión en vivo de la presentación a través del sitio web de relaciones con inversores de Kodiak en ir.kodiak.com, donde también estará disponible para reproducción por un tiempo limitado después del evento.
망막 질환 치료제 개발에 주력하는 바이오제약 회사 Kodiak Sciences(NASDAQ: KOD)는 CEO 빅터 펄로스가 2025년 제퍼리스 글로벌 헬스케어 컨퍼런스에서 발표할 예정이라고 발표했습니다. 발표는 2025년 6월 5일 오전 9시 20분(동부시간) 뉴욕시에서 진행됩니다. 투자자들은 Kodiak의 투자자 관계 웹사이트 ir.kodiak.com을 통해 발표 라이브 웹캐스트에 접속할 수 있으며, 행사 후 일정 기간 동안 다시보기로도 제공됩니다.
Kodiak Sciences (NASDAQ : KOD), une société biopharmaceutique spécialisée dans le développement de traitements pour les maladies rétiniennes, a annoncé que son PDG, Victor Perlroth, présentera lors de la conférence mondiale sur la santé Jefferies 2025. La présentation est prévue le 5 juin 2025 à 9h20 (heure de l'Est) à New York. Les investisseurs pourront suivre la présentation en direct via le site web des relations investisseurs de Kodiak à l'adresse ir.kodiak.com, où elle restera disponible en replay pendant une durée limitée après l'événement.
Kodiak Sciences (NASDAQ: KOD), ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung von Behandlungen für Netzhauterkrankungen spezialisiert hat, gab bekannt, dass CEO Victor Perlroth auf der Jefferies Global Healthcare Conference 2025 präsentieren wird. Die Präsentation ist für den 5. Juni 2025 um 9:20 Uhr ET in New York City geplant. Investoren können die Präsentation live über den Investor-Relations-Bereich von Kodiak unter ir.kodiak.com verfolgen, wo sie nach der Veranstaltung für kurze Zeit als Aufzeichnung verfügbar sein wird.
Positive
  • None.
Negative
  • None.

PALO ALTO, Calif., May 29, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that Victor Perlroth, M.D., Chief Executive Officer, will present at the 2025 Jefferies Global Healthcare Conference in New York City, NY on Thursday, June 5, 2025, at 9:20am ET (6:20am PT).

A live webcast of the presentation will be available on the "Events and Presentations" section of Kodiak's website at http://ir.kodiak.com/ and will remain available for replay for a limited time following the event.

About Kodiak Sciences Inc. 

Kodiak Sciences (Nasdaq: KOD) is a precommercial retina focused biotechnology company committed to researching, developing, and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases. We are focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. Our ABC Platform® uses molecular engineering to merge the fields of protein-based and chemistry-based therapies and is at the core of Kodiak's discovery engine. Kodiak's maturing pipeline includes three late-phase clinical assets, all three targeting Phase 3 topline data in 2026.

For more information, please visit www.kodiak.com

Kodiak®, Kodiak Sciences®, ABC®, ABC Platform®, ABCD™ and the Kodiak logo are registered trademarks or trademarks of Kodiak Sciences Inc. in various global jurisdictions.

Cision View original content:https://www.prnewswire.com/news-releases/kodiak-sciences-to-present-at-2025-jefferies-global-healthcare-conference-302469141.html

SOURCE Kodiak Sciences Inc.

FAQ

When is Kodiak Sciences (KOD) presenting at the 2025 Jefferies Healthcare Conference?

Kodiak Sciences will present on Thursday, June 5, 2025, at 9:20am ET (6:20am PT) in New York City.

Who will represent Kodiak Sciences (KOD) at the Jefferies Healthcare Conference 2025?

Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences, will present at the conference.

How can investors watch Kodiak Sciences' (KOD) presentation at the Jefferies conference?

Investors can watch the live webcast through the 'Events and Presentations' section of Kodiak's website at ir.kodiak.com.

What is Kodiak Sciences' (KOD) main business focus?

Kodiak Sciences is a biopharmaceutical company focused on researching, developing and commercializing therapeutics for retinal diseases.
Kodiak Sciences Inc.

NASDAQ:KOD

KOD Rankings

KOD Latest News

KOD Stock Data

187.05M
49.85M
4.65%
80.44%
4.42%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
PALO ALTO